Name | Xanomeline oxalate |
Description | Xanomeline oxalate (LY246708 oxalate), a potent and selective muscarinic receptor agonist (SMRA), effectively stimulates in vivo phosphoinositide hydrolysis. It is a valuable compound for Alzheimer's disease research. |
In vitro | Xanomeline stimulates phosphoinositide (PI) hydrolysis in A9 L m1 cells and inhibits [3H]-PZ and [3H]-OXO-M binding to rat brain, with Kis of 7 and 3 nM, respectively[1]. |
In vivo | Xanomeline robustly stimulates in vivo PI hydrolysis, an effect blocked by muscarinic antagonists, indicating mediation by muscarinic receptors. In mice, the ED100 for Xanomeline-induced stimulation of [3H]-IP accumulation in the hippocampus is 54 μmole/kg, while in rats, it is 8.1 μmole/kg in the hippocampus[1]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 45 mg/mL (121.15 mM), Sonication is recommended.
|
Keywords | Xanomeline Oxalate | muscarinic receptor | LY-246708 Oxalate | LY246708 Oxalate | LY 246708 Oxalate |
Inhibitors Related | Adiphenine hydrochloride | Nanofin | Forskolin | Pilocarpine Hydrochloride | (+)-Sparteine | Clozapine N-Oxide | Pilocarpine nitrate | Ribavirin | D-Menthol | Amitriptyline hydrochloride | Choline chloride | Propoxur |
Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Failed Clinical Trials Compound Library | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Approved Drug Library | Anti-Alzheimer's Disease Compound Library | Membrane Protein-targeted Compound Library | Neurotransmitter Receptor Compound Library | Drug Repurposing Compound Library | FDA-Approved Drug Library | Clinical Compound Library | Bioactive Compounds Library Max |